Revance Therapeutics (NASDAQ:RVNC) Now Covered by StockNews.com

Equities researchers at StockNews.com began coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research report issued on Thursday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

RVNC has been the subject of a number of other reports. Mizuho reduced their target price on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a report on Tuesday, December 10th. Barclays dropped their price target on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Monday, December 23rd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a research report on Friday, January 17th. Nine equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $8.39.

Revance Therapeutics Price Performance

Shares of Revance Therapeutics stock opened at $3.65 on Thursday. The firm’s fifty day simple moving average is $3.65 and its 200-day simple moving average is $4.08. Revance Therapeutics has a 12 month low of $2.30 and a 12 month high of $6.65. The stock has a market capitalization of $381.02 million, a price-to-earnings ratio of -1.89 and a beta of 0.90.

Hedge Funds Weigh In On Revance Therapeutics

A number of large investors have recently modified their holdings of the business. CIBRA Capital Ltd acquired a new position in Revance Therapeutics during the fourth quarter worth $3,466,000. Alpine Global Management LLC purchased a new stake in Revance Therapeutics during the fourth quarter worth about $37,000. Two Sigma Investments LP grew its position in Revance Therapeutics by 8.6% during the fourth quarter. Two Sigma Investments LP now owns 170,136 shares of the biopharmaceutical company’s stock worth $517,000 after buying an additional 13,539 shares during the period. ProShare Advisors LLC increased its holdings in Revance Therapeutics by 19.3% in the fourth quarter. ProShare Advisors LLC now owns 75,252 shares of the biopharmaceutical company’s stock valued at $229,000 after buying an additional 12,155 shares in the last quarter. Finally, Man Group plc lifted its position in shares of Revance Therapeutics by 47.8% during the 4th quarter. Man Group plc now owns 443,544 shares of the biopharmaceutical company’s stock valued at $1,348,000 after acquiring an additional 143,544 shares during the period. 97.70% of the stock is owned by hedge funds and other institutional investors.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.